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  cis－Diamminedichloroplatinum （cisplatin） treatment for urogenital malignancies was presented as
phase 1 and phase II studies． Five cases， including 3 cases of bladder tumor， one of ureteral tumor
and one．of Wil．msl． tumor， were subjected to phase 1 study． 1．t was demonstrated that cisplatin was
SafelY’№奄魔?Dh in’a d6．Shge’ of’10’rr｝g for 5 ’c6nsecutive days． Adverse effects were mainly gastrointestinal，
suCh’a． s nauts’ea， V6miting， ahd hn6r6kiaL Nin． e cases， including 8 cases of testicular tumor and ohe
of renal cell carcinoma， were subjected to phase II study， KoYama－Saito’s and Karnofsky’s criteria
werc ．adopted’ for the evaluhti’on of clipical effectiveness． Cisplatin was given in a total dosage of
160 mg－790 mg．． Ov¢rall respops¢ rate was 22．20／，． ln terms of testicular tumor it was 250／o．
A死面9．．亡h6 6alie6．諦i伍t6sticula士．ttim6r， one showed complete remissioll with complcte d呈sappearance
ofpulmonary metastases． Toxicities were the same as seen in phase I study． Nephrotoxicity， difllculty
of hearing， hematopoietic toxicity and hepatotoxicity were not major problems in this series ofpatients．
From these studies it was assumed that this agent was effective for the treatment of urogenital ma｝ig－
nancies， especially testicular tumor．























 症例1，2，3，4，5はphase I study，それ以外
の症例はphase II studyの対象である．
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Fig． 1． Clinical course of testicular tumor treated with Cis－platin
Table 1． Cases of urogenital malignancy treated with cisplatin
｝O． Name Age Sex Diagnosis 1］NM
                               2）        1）                  KOYAMA，           Doses （mg）Method of                   Karnofsky SAITO’SAdministration qvJ Total                           CRITERIA










































Ureteral turnor， Tr icell ca．
Bladder tumor， Tr．eell ca．
Bladder tumor， Tr．cell ca．
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  CR： Complete response
  PR： Partial response
  uc： Unehanged
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（phase I， II study）の成績について自験14例塗中心
に報告した．
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